News | March 13, 2023
Zydus receives final approval from the USFDA for Olanzapine
Olanzapine Orally Disintegrating Tablets are used to treat certain mental/mood conditions
Olanzapine Orally Disintegrating Tablets are used to treat certain mental/mood conditions
The Development Center with its state-of-the art laboratories and flexible pilot capacities is set to become Siegfried's global research and development hub for its Drug Products sites, strengthening the global network
New GMP facility for clinical and small-scale commercial pharmaceutical lipids
The approved product is indicated for the treatment of adult patients with Multiple myeloma, in combination with Dexamethasone
The new powder flow tester can characterize powder flow properties, offering valuable insight for pharmaceutical processing and formulation
The common stock of Concert will no longer be listed for trading on the Nasdaq Global Market
Projected ~US$100 million cash balance of combined company expected to fund operations through mid-2025 and to clinical data over the next 12 to 24 months
New subgroup analysis from Phase III ARASENS trial shows that darolutamide plus androgen deprivation therapy (ADT) in combination with docetaxel increased overall survival (OS)
_256_384.png)
Data show 37% reduction in risk of disease progression or death in men with metastatic castration-resistant prostate cancer treated with TALZENNA plus XTANDI
Label expansion for CIBINQO provides new systemic oral option for adolescents (12 to <18 years) with moderate-to-severe atopic dermatitis
Subscribe To Our Newsletter & Stay Updated
